Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Vitamin K (Phylloquinone) is scientifically validated for the treatment and prevention of internal bleeding, particularly when bleeding is due to vitamin K deficiency or as a result of anticoagulant (e.g., warfarin) overdose. Vitamin K plays a crucial role in the synthesis of clotting factors II, VII, IX, and X in the liver, all of which are essential for normal blood coagulation. Deficiency in vitamin K impairs the production of these clotting factors, leading to an increased risk of bleeding, which can be spontaneous and internal (e.g., gastrointestinal or intracranial hemorrhage).

Clinical guidelines and multiple studies support the use of vitamin K for reversing anticoagulation caused by warfarin, as well as for treating bleeding due to vitamin K deficiency in both adults and neonates. Injectable and oral forms of vitamin K are routinely used in hospitals to manage these conditions. In neonatology, prophylactic vitamin K administration at birth is a standard practice to prevent hemorrhagic disease of the newborn, a potentially life-threatening condition.

The efficacy and safety of vitamin K in these scenarios are well established. Its use is not based on tradition, but on a solid understanding of its biochemistry, physiology, and extensive clinical evidence. Therefore, vitamin K is a first-line, scientifically validated therapy for internal bleeding when due to its deficiency or to reverse the effects of vitamin K antagonists.

More about Vitamin K (Phylloquinone)
More about Bleeding (internal)

Other ingredients used for Bleeding (internal)

Other health conditions supported by Vitamin K (Phylloquinone)

Products containing Vitamin K (Phylloquinone)